Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 3
1997 3
1999 2
2001 2
2002 1
2003 2
2004 4
2005 4
2006 1
2008 1
2009 3
2010 3
2012 4
2013 6
2014 5
2015 6
2016 5
2017 1
2018 6
2019 5
2020 5
2021 6
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease.
Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, Kostara CE. Kosmas CE, et al. Diagnostics (Basel). 2023 Mar 1;13(5):929. doi: 10.3390/diagnostics13050929. Diagnostics (Basel). 2023. PMID: 36900073 Free PMC article. Review.
A disturbed lipid metabolism and the subsequent dyslipidemia significantly contribute to the formation of plaques, with low-density lipoprotein cholesterol (LDL-C) being the main responsible factor. Nonetheless, even when LDL-C is well regulated, mainly with statin …
A disturbed lipid metabolism and the subsequent dyslipidemia significantly contribute to the formation of plaques, with low-density lipoprot …
Inclisiran in dyslipidemia.
Kosmas CE, Muñoz Estrella A, Sourlas A, Pantou D. Kosmas CE, et al. Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083. Drugs Today (Barc). 2021. PMID: 34061126 Review.
However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subs …
However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are into …
Environmental Factors Modifying HDL Functionality.
Kosmas CE, Sourlas A, Guzman E, Kostara CE. Kosmas CE, et al. Curr Med Chem. 2022;29(10):1687-1701. doi: 10.2174/0929867328666210714155422. Curr Med Chem. 2022. PMID: 34269662 Review.
BACKGROUND: Currently, it has been recognized that High-Density Lipoprotein (HDL) functionality plays a much more essential role in protection from atherosclerosis than circulating HDLcholesterol (HDL-C) levels per se. Cholesterol efflux capacity (CEC) from macrophages to …
BACKGROUND: Currently, it has been recognized that High-Density Lipoprotein (HDL) functionality plays a much more essential role in protecti …
Anti-inflammatory therapy for cardiovascular disease.
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E, Garcia MJ. Kosmas CE, et al. Ann Transl Med. 2019 Apr;7(7):147. doi: 10.21037/atm.2019.02.34. Ann Transl Med. 2019. PMID: 31157268 Free PMC article. Review.
Chronic subclinical inflammation is a central process in the pathogenesis of cardiovascular disease (CVD) and it has been linked with both the initiation and progression of atherosclerosis. Several pro-inflammatory cytokines, such as the C-reactive protein (CRP), tumor nec …
Chronic subclinical inflammation is a central process in the pathogenesis of cardiovascular disease (CVD) and it has been linked with both t …
CETP Inhibition: Past Failures and Future Hopes.
Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. Kosmas CE, et al. Clin Med Insights Cardiol. 2016 Mar 13;10:37-42. doi: 10.4137/CMC.S32667. eCollection 2016. Clin Med Insights Cardiol. 2016. PMID: 26997876 Free PMC article. Review.
The atheroprotective role of high-density lipoprotein cholesterol (HDL-C) in cardiovascular disease has been unequivocally established, and epidemiological data have clearly demonstrated a strong inverse relationship between HDL-C levels and the risk of cardiovascul …
The atheroprotective role of high-density lipoprotein cholesterol (HDL-C) in cardiovascular disease has been unequivocally establishe …
New and Emerging LDL Cholesterol-Lowering Drugs.
Kosmas CE, Frishman WH. Kosmas CE, et al. Am J Ther. 2015 May-Jun;22(3):234-41. doi: 10.1097/MJT.0000000000000063. Am J Ther. 2015. PMID: 25486520 Review.
However, until recently, the efficacy of other non-statin LDL-C-lowering drugs was modest, not exceeding a LDL-C reduction of 20%. ...This review aims to provide the current evidence regarding the newly approved LDL-C-lowering agents, as well as the clinical …
However, until recently, the efficacy of other non-statin LDL-C-lowering drugs was modest, not exceeding a LDL-C reduction of …
New and emerging lipid-modifying drugs to lower LDL cholesterol.
Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E. Kosmas CE, et al. Drugs Context. 2021 Nov 1;10:2021-8-3. doi: 10.7573/dic.2021-8-3. eCollection 2021. Drugs Context. 2021. PMID: 34795777 Free PMC article. Review.
However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. ...This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering …
However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. ...This review a …
High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease.
Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, Montan PD, Guzman E. Kosmas CE, et al. Drugs Context. 2018 Mar 28;7:212525. doi: 10.7573/dic.212525. eCollection 2018. Drugs Context. 2018. PMID: 29623098 Free PMC article. Review.
Several prospective epidemiological studies have shown that there is a clear inverse relationship between serum high-density lipoprotein-cholesterol (HDL-C) concentrations and risk for coronary heart disease (CHD), even at low-density lipoprotein-cholesterol (LDL-C) …
Several prospective epidemiological studies have shown that there is a clear inverse relationship between serum high-density lipoprotein-cho …
Inflammation in coronary artery disease.
Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE. Christodoulidis G, et al. Cardiol Rev. 2014 Nov-Dec;22(6):279-88. doi: 10.1097/CRD.0000000000000006. Cardiol Rev. 2014. PMID: 24441047 Review.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.
Kosmas CE, Sourlas A, Bouza KV, DeJesus E, Silverio D, Montan PD, Guzman E. Kosmas CE, et al. Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20. Ann Transl Med. 2018. PMID: 29955590 Free PMC article. No abstract available.
80 results